Every material Form 8-K Longeveron Inc. has filed with the SEC since October 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Longeveron Inc. said director Ursula Ungaro resigned immediately on November 1, 2026, from its Board of Directors and from its Audit, Compensation, Nominating and Corporate Governance, and Special Committees. She cited personal health issues and said the decision was not due to any disagreement with the company on operations, policies or practices.
Resignation notice given November 1, 2026, effective immediately
Ms. Ungaro left the Board and four board committees: Audit, Compensation, Nominating and Corporate Governance, and Special
Stated reason is personal health issues; no disagreement with the company is reported
The filing does not name a replacement director or describe any succession plan
Longeveron reported updated ELPIS II Phase 2b results for laromestrocel in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary endpoint of change in right ventricular ejection fraction at Month 12, but a pre-specified secondary endpoint, major adverse cardiac events (MACE), reached statistical significance. The company plans to request an FDA meeting, and the results are scheduled for presentation at the AHA 2026 Scientific Sessions.
Primary endpoint not met: mean RVEF decreased 2.6 percentage points in the standard of care group and 3.3 points in the laromestrocel group, with no statistically significant difference (p=0.68).
MACE: 8 events in the standard of care arm versus 1 in the laromestrocel arm (P=0.043).
FDA previously advised Longeveron that RVEF alone would not be sufficient to demonstrate efficacy for regulatory approval.
Data selected for a late-breaking podium presentation at AHA 2026 Scientific Sessions on November 8, 2026, in Chicago.
Longeveron Inc. disclosed that Chief Medical Officer Dr. Nataliya Agafonova informed management on October 7, 2026, of her decision to step down, effective October 14, 2026. The filing does not state a successor or the reason for her departure.
Dr. Nataliya Agafonova informed management on October 7, 2026, of her decision to step down as Chief Medical Officer.
The departure takes effect October 14, 2026.
The filing does not name a replacement or give a reason for the departure.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Longeveron Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →